Investing

X4 Pharmaceuticals : XFOR

XFOR

Stock Data

$4.19

$0.12 (2.95%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

X4 Pharmaceuticals Inc is a biopharmaceutical company based in Boston, Massachusetts, dedicated to creating treatments for rare diseases. Its flagship project, mavorixafor, is a promising drug in advanced clinical trials aimed at addressing a range of conditions, including a syndrome characterized by warts, immune deficiencies, and infections. Additionally, X4 Pharmaceuticals is exploring potential therapies for brain cancers and other disorders linked to the CXCR4 receptor. The company collaborates with Abbisko Therapeutics for oncology treatments, showcasing its commitment to innovative healthcare solutions.

All X4 Pharmaceuticals Articles

1 Article

Joel South | Mar 9, 2026 at 11:15 AM EDT

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional…